1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,140 | 3,420 | 19:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | JUNSHI BIO (01877): 2025 INTERIM REPORT | - | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | UBS stuft Shanghai Junshi Biosciences wegen hoher Bewertung auf "Neutral" herab | 1 | Investing.com Deutsch | ||
| Do | UBS downgrades Shanghai Junshi Biosciences stock to Neutral on valuation | 1 | Investing.com | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL FORM OF PROXY FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 29 SEPTEMBER 2025 | 2 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL CIRCULAR PROPOSED GRANT OF H SHARE OPTIONS TO EXECUTIVE DIRECTORS AND ASSOCIATES OF SUBSTANTIAL SHAREHOLDERS AND SUPPLEMENTAL ... | 1 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 12.09. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ... | - | HKEx | ||
| 08.09. | Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators | 1 | FierceBiotech | ||
| 07.09. | Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints | 535 | GlobeNewswire (Europe) | SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 05.09. | JUNSHI BIO (01877): 2025 FIRST EGM CIRCULAR | - | HKEx | ||
| 05.09. | JUNSHI BIO (01877): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 05.09. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, 26 SEPTEMBER 2025 | - | HKEx | ||
| 05.09. | JUNSHI BIO (01877): PROPOSED ELECTION AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE ... | - | HKEx | ||
| 05.09. | JUNSHI BIO (01877): RULES RELATING TO THE 2025 H SHARE OPTION INCENTIVE SCHEME | - | HKEx | ||
| 05.09. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx | ||
| 02.09. | JUNSHI BIO (01877): (1) PROPOSED ADOPTION OF THE 2025 H SHARE OPTION INCENTIVE SCHEME; (2) PROPOSED GRANT OF H SHARE OPTIONS TO THE GRANTEES; (3) PROPOSED ... | 1 | HKEx | ||
| 02.09. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JT118 RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL | 1 | HKEx | ||
| 02.09. | JPMorgan stuft Shanghai Junshi Biosciences auf 'Underweight' herab | 1 | Investing.com Deutsch | ||
| 02.09. | JPMorgan downgrades Shanghai Junshi Biosciences stock to Underweight | 1 | Investing.com |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,515 | -0,35 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| BIONTECH | 83,90 | +0,06 % | BioNTech SE: BioNTech veranstaltet am 1. Oktober 2025 zweiten "AI Day" als eine Ausgabe der "Innovation Series" | MAINZ, Deutschland, 23. September 2025("InstaDeep"), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten "AI Day" aus, eine Ausgabe von BioNTechs "Innovation Series"... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 5,280 | +54,84 % | Bioaffinity Technologies stock soars after lung cancer test aids early detection | ||
| RECURSION PHARMACEUTICALS | 4,725 | +2,05 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| EVOTEC | 5,932 | -1,76 % | AJN Resources, TUI, Evotec: Frisches Kapital und Insiderkäufe! | Frisches Kapital, Insiderkäufe oder wichtige Veränderungen im Aktionärskreis können wichtige Signale in Bezug auf die zukünftige Aktienkursentwicklung geben. Gerade bei kleineren Unternehmen ist der... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,980 | -0,48 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,970 | +3,50 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
| INDAPTUS THERAPEUTICS | 3,490 | +6,40 % | Indaptus Therapeutics Provides Clinical Update | Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 56,29 | +4,65 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| 89BIO | 14,700 | 0,00 % | Roche To Buy 89bio For Up To $3.5 Billion | ||
| AVIDITY BIOSCIENCES | 42,880 | +4,97 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,985 | +3,83 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 18,030 | +5,01 % | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 61,93 | +9,84 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| MBX BIOSCIENCES | 17,535 | +1,18 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,200 Euro und damit -3,03 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.